Future programs

Beyond the three rare bleeding disorder programs, there are several other monogenetic diseases that can also be targeted with a similar approach as with rare bleeding disorders. Those proteins which are also naturally produced in the liver can also be targets with SanaGen’s capabilities, including liver cell directed vectors and promoters. 

Through our partnership with Professor Joost Verhaagen, SanaGen has also embarked on starting research to develop novel gene therapy treatments for central nervous system (CNS) disorders.